Senate Maintains Funding Levels for Most HIV and Hepatitis Programs

The Senate Labor, Health and Human Services, and Education Appropriations Subcommittee approved its Fiscal Year 2017 funding bill that largely maintains funding for most domestic HIV programs.  However, the bill proposes to cut some critical programs, including $29 million from the Ryan White HIV/AIDS Program and $6 million from the Minority AIDS Initiative, and provides no increases for hepatitis prevention programs at the CDC.

To read the full press release from The AIDS Institute on the subcommittee markup, click the PDF below

The AIDS Institute Ryan White Program Funding Analysis by State

In order to increase viral suppression and  improve health outcomes for people living with HIV/AIDS in the United States, the National HIV/AIDS Strategy calls for federal  funding to follow the epidemic and be distributed to areas most in need.  This is a principle The AIDS Institute has long supported and championed.  In an effort to determine whether current Ryan White HIV/AIDS Program funding is being distributed proportionately to those areas where it is needed, particularly now that hold harmless provisions have ended, we conducted an analysis of Ryan White Program

Florida to Continue Patient Cost-sharing Limits for HIV Drugs in 2017

The AIDS Institute praises the Florida Office of Insurance Regulation (FOIR) for requiring insurers to again limit patient cost-sharing for HIV medications as they submit for review their 2017 Qualified Health Plans (QHPs).

Senate Committee Acts to More Fairly Distribute AIDS Housing Funds

The Senate Transportation, Housing and Urban Development, and Related Agencies Appropriations Subcommittee has acted to more fairly distribute AIDS housing funds. “We applaud Sens.

Letter to FL Insurance Commissioner on lack of coverage for HCV drugs in QHPs in Florida

Below is a letter to the Florida Insurance Commissioner concerning insurance coverage or lack thereof for Hepatitis C drugs for insureds enrolled in Qualified Health Plans in Florida. The AIDS Institute joins AfPA in this request. We write with the hope that formal dispute resolution or litigation can be avoided but time is short and the crisis is real.

AIDS Foundation of Chicago and The AIDS Institute Recognize Ambetter for Increasing HIV Medication Coverage

Below is a press release from The AIDS Foundation of Chicago and The AIDS Institute reporting that through their joint advocacy, national health insurance provider Ambetter Health has agreed to expand the list of medications it covers to include life-saving daily treatments for people living with HIV. 

FY17 Dear Colleague letters

Below are the Dear Colleague letters for domestic HIV/AIDS and hepatitis programs in the House and Senate 

AIDS Budget and Appropriations Coalition's FY2017 Letter to Congress

Below is the FY2017 AIDS Budget and Appropriations Coalition's FY2017 Sign-on letter to members of Congress urging continued and adequate support for domestic HIV/AIDS programs. 

President Obama’s Budget Maintains Commitment to Domestic HIV and Hepatitis Programs

“The budget President Obama released today demonstrates his Administration’s continued commitment to preventing HIV and hepatitis in the United States and providing lifesaving health care and treatment for those who cannot afford it,” commented Carl Schmid, Deputy Executive Director of The AIDS Institute.  “While it contains very few program funding increases, there is a new proposed CDC initiative that allows health departments to spend a portion of their funding on pre-exposure prophylaxis (

I Am Essential Comments on Draft 2017 Letter to Issuers in the Federally-facilitated Marketplaces

Below are the comments from the I Am Essential coalition on the Draft 2017 Letter to Issuers in the Federally-facilitated Marketplaces. In the coalition's letter, we thank CMS for requiring QHPs to include many important patient protections and reminders that plans cannot discriminate against beneficiaries, especially those with serious health needs.  However, we reiterate the need for CMS and the states to actually enforce these patient protections and call out discriminatory plan design.

Syndicate content